2 Beaten-Down Stocks With Incredible Upside Potential

Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,000% over the past three years, and Abivax, a France-based drugmaker, is up by more than 800% this year following strong clinical data.Of course, chasing quick gains is not a reliable investing strategy. But some clinical-stage biotechs could deliver superior returns over the long run, provided their master plans come to fruition.Here are two examples: Viking Therapeutics (NASDAQ: VKTX) and Recursion Pharmaceuticals (NASDAQ: RXRX). These biotechs, both of which have outperformed the market this year, could have massive upside potential -- but there's also risk involved.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool